Allergic sensitization to pegylated interferon‐α results in drug eruptions - Meller, S.; Gerber, P. A.; Kislat, A.; Hevezi, P.; Göbel, T.; Wiesner, U.; Kellermann, S.; Bünemann, E.; Zlotnik, A.; Häussinger, D.; Erhardt, A.; Homey, B. (Allergy (Copenhagen), 2015)
Keywords: Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; chemokines; Cytokines - genetics; Cytokines - metabolism; drug eruption; Drug Eruptions - diagnosis; Drug Eruptions - etiology; Gene Expression; Hepatitis C virus; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Humans; Interferon Regulatory Factors - genetics; Interferon Regulatory Factors - metabolism; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Lymphocyte Activation; lymphocyte activation test; maculopapular exanthema; pegylated Interferon; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Skin - pathology; Skin Tests; T-Lymphocyte Subsets - immunology; T-Lymphocyte Subsets - metabolism; pegylated Interferon; drug eruption; maculopapular exanthema; lymphocyte activation test; chemokines